In a nutshell This study investigated the effectiveness and safety of a new hormonal therapy, SHR3680 (rezvilutamide), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that SHR680 was well tolerated and had promising effectiveness in these patients. Some background Metastatic...
Read More
In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...
Read More
In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...
Read More
In a nutshell This study evaluated the effectiveness of radiotherapy (RT) plus androgen receptor-targeted therapy (ARTT) on oligo-progressive sites for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that RT on oligo-progressive sites was safe and effective in prolonging treatment with ARTT in...
Read More
In a nutshell This study compared 2 approaches of robot-assisted radical prostatectomy (RARP) for the treatment of localized prostate cancer (PCa). The authors concluded that both transvesical (T) and posterior (P) approaches had similar results in these patients. Some background Localized prostate cancer (PCa) is cancer that is...
Read More
In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients. Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...
Read More
In a nutshell The study aimed to understand the long-term outcomes of focal laser therapy (FLT) in patients with prostate cancer. The study showed that this treatment has long-term survival without recurrence in certain patients. Some background Surgical removal of the prostate gland is often recommended as a treatment for...
Read More
In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...
Read More
In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...
Read More
In a nutshell This study explored the outcomes of statin (cholesterol-lowering drugs) treatment in patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The authors found that the combination of statins and ADT improved the outcomes of these patients and intermittent ADT (IADT) increased the time...
Read More
In a nutshell This study aims to evaluate if giving radiotherapy to both the areas the tumor has spread (metastases), along with the prostate tumor, will improve the survival of patients with prostate cancer (PC) and few metastases (oligometastatic disease). This study suggested that this treatment could benefit patients with PC and few...
Read More
In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...
Read More
